Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration

被引:115
作者
Farfel-Becker, Tamar [1 ]
Vitner, Einat B. [1 ]
Kelly, Samuel L. [3 ,4 ]
Bame, Jessica R. [3 ,4 ]
Duan, Jingjing [3 ,4 ]
Shinder, Vera [2 ]
Merrill, Alfred H., Jr. [3 ,4 ]
Dobrenis, Kostantin [5 ]
Futerman, Anthony H. [1 ]
机构
[1] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel
[2] Weizmann Inst Sci, Dept Chem Res Support, IL-76100 Rehovot, Israel
[3] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA
[4] Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA
[5] Yeshiva Univ Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA
关键词
PARKINSONS-DISEASE; GLUCOSYLSPHINGOSINE ACCUMULATION; GLUCOCEREBROSIDASE MUTATIONS; STORAGE DISORDERS; FINE STRUCTURE; INFANTILE; TYPE-2; NEUROPATHOLOGY; SPHINGOLIPIDS; METABOLISM;
D O I
10.1093/hmg/ddt468
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gaucher disease has recently received wide attention due to the unexpected discovery that it is a genetic risk factor for Parkinsons disease. Gaucher disease is caused by the defective activity of the lysosomal enzyme, glucocerebrosidase (GCase; GBA1), resulting in intracellular accumulation of the glycosphingolipids, glucosylceramide and psychosine. The rare neuronopathic forms of GD (nGD) are characterized by profound neurological impairment and neuronal cell death. We have previously described the progression of neuropathological changes in a mouse model of nGD. We now examine the relationship between glycosphingolipid accumulation and initiation of pathology at two pre-symptomatic stages of the disease in four different brain areas which display differential degrees of susceptibility to GCase deficiency. Liquid chromatography electrospray ionization tandem mass spectrometry demonstrated glucosylceramide and psychosine accumulation in nGD brains prior to the appearance of neuroinflammation, although only glucosylceramide accumulation correlated with neuroinflammation and neuron loss. Levels of other sphingolipids, including the pro-apoptotic lipid, ceramide, were mostly unaltered. Transmission electron microscopy revealed that glucosylceramide accumulation occurs in neurons, mostly in the form of membrane-delimited pseudo-tubules located near the nucleus. Highly disrupted glucosylceramide-storing cells, which are likely degenerating neurons containing massive inclusions, numerous autophagosomes and unique ultrastructural features, were also observed. Together, our results indicate that a certain level of neuronal glucosylceramide storage is required to trigger neuropathological changes in affected brain areas, while other brain areas containing similar glucosylceramide levels are unaltered, presumably because of intrinsic differences in neuronal properties, or in the neuronal environment, between various brain regions.
引用
收藏
页码:843 / 854
页数:12
相关论文
共 53 条
  • [11] NEUROPATHOLOGY OF THE NORRBOTTNIAN TYPE OF GAUCHER DISEASE - MORPHOLOGICAL AND BIOCHEMICAL-STUDIES
    CONRADI, NG
    SOURANDER, P
    NILSSON, O
    SVENNERHOLM, L
    ERIKSON, A
    [J]. ACTA NEUROPATHOLOGICA, 1984, 65 (02) : 99 - 109
  • [12] Murine models of acute neuronopathic Gaucher disease
    Enquist, Ida Berglin
    Lo Bianco, Christophe
    Ooka, Andreas
    Nilsson, Eva
    Mansson, Jan-Eric
    Ehinger, Mats
    Richter, Johan
    Brady, Roscoe O.
    Kirik, Deniz
    Karlsson, Stefan
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (44) : 17483 - 17488
  • [13] Animal models for Gaucher disease research
    Farfel-Becker, Tamar
    Vitner, Einat B.
    Futerman, Anthony H.
    [J]. DISEASE MODELS & MECHANISMS, 2011, 4 (06) : 746 - 752
  • [14] Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease
    Farfel-Becker, Tamar
    Vitner, Einat B.
    Pressey, Sarah N. R.
    Eilam, Raya
    Cooper, Jonathan D.
    Futerman, Anthony H.
    [J]. HUMAN MOLECULAR GENETICS, 2011, 20 (07) : 1375 - 1386
  • [15] Cellular pathogenesis in sphingolipid storage disorders: the quest for new therapeutic approaches
    Farfel-Becker, Tamar
    Futerman, Anthony H.
    [J]. CLINICAL LIPIDOLOGY, 2010, 5 (02) : 255 - 265
  • [16] No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease
    Farfel-Becker, Tamar
    Vitner, Einat
    Dekel, Hani
    Leshem, Noa
    Enquist, Ida Berglin
    Karlsson, Stefan
    Futerman, Anthony H.
    [J]. HUMAN MOLECULAR GENETICS, 2009, 18 (08) : 1482 - 1488
  • [17] Type 2 Gaucher disease: Phenotypic variation and genotypic heterogeneity
    Gupta, N.
    Oppenheim, I. M.
    Kauvar, E. F.
    Tayebi, N.
    Sidransky, E.
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 2011, 46 (01) : 75 - 84
  • [18] Ocular motor abnormalities in Gaucher disease
    Harris, CM
    Taylor, DSI
    Vellodi, A
    [J]. NEUROPEDIATRICS, 1999, 30 (06) : 289 - 293
  • [19] INFANTILE NEUROLOGICAL GAUCHERS-DISEASE IN 3 SIBLINGS - ULTRASTRUCTURAL STUDY
    HERNANDEZ, F
    BUENO, M
    [J]. VIRCHOWS ARCHIV ABTEILUNG A PATHOLOGISCHE ANATOMIE, 1973, 360 (01): : 27 - 32
  • [20] Gaucher disease: pathological mechanisms and modern management
    Jmoudiak, M
    Futerman, AH
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (02) : 178 - 188